Wellwise Pharmacy Inc.; Decision and Order

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Justice Drug Enforcement Administration On September 25, 2025, the Drug Enforcement Administration (DEA or Government) issued an Order to Show Cause and Immediate Suspension of Registration (OSC/ISO) to Wellwise Pharmacy Inc. of Houston, Texas, and Conroe, Texas (Registrant). Request for Final Agency Action (RFAA), Exhibit (RFAAX) 1, at 1, 11. The OSC/ISO informed Registrant of the immediate suspension of its DEA registration, No. FW2318497, pursuant to 21 U.S.C. 824(d) , finding that Registrant's continued registration constitutes “ `an imminent danger to the public health or safety.' ” Id. at 1 (quoting 21 U.S.C. 824(d) ). The OSC/ISO also proposed the revocation of Registrant's registration, alleging that Registrant's continued registration is inconsistent with the public interest. Id. at 1 (citing 21 U.S.C. 823(g)(1) , 824(a)(4) ). [ 1 ] Specifically, the OSC/ISO alleges that from at least January 2023 to March 2025, Registrant violated federal and Texas law by repeatedly filling prescriptions for controlled substances that presented multiple flags of diversion and/or abuse without addressing or resolving those red flags. RFAAX 1, at 4. The OSC/ISO alleged that these unresolved red flags of abuse and/or diversion included pattern prescribing; prescriptions for controlled substances commonly known to be abused; prescriptions for controlled substances at their highest strength and/or in large quantities; prescriptions for controlled s…